In CM, the combination of MEKi plus CDK4/6i reduces tumor growth in vitro and in vivo, across genomic subtypes, and in BRAFi/MEKi-resistant patient-derived xenografts (Nassar et al., 2021; Posch et al., 2018; Teh et al., 2016). This evidence concerns the gene CDK4 and neoplasm.